Syndrome-linked CK 2 α mutations have reduced kinase activity

The Okur-Chung Neurodevelopmental Syndrome, or OCNDS, is a newly discovered rare neurodevelopmental disorder. It is characterized by developmental delay, intellectual disability, behavioral problems (hyperactivity, repetitive movements and social interaction deficits), hypotonia, epilepsy and language/verbalization deficits. OCNDS is linked to de novo variants in CSNK2A1, that lead to missense or deletion/truncating mutations in the encoded protein, the protein kinase CK2α. Eighteen different missense CK2α mutants have been identified to date, however no biochemical or cell biological studies have yet been performed to clarify the functional impact of such mutations. Here, we show that 15 different missense CK2α mutations lead to varying degrees of loss of kinase activity as recombinant purified proteins and when mutants are ectopically expressed in mammalian cells. We further detect changes in the phosphoproteome of three patient derived fibroblast lines and show that the subcellular localization of CK2α is altered for some of the OCNDS-linked mutants and in patient derived fibroblasts. Our data argue that reduced kinase activity and abnormal localization of CK2α may underlie the OCNDS phenotype.

[1]  Osmany Guirola,et al.  CIGB-300 anticancer peptide regulates the protein kinase CK2-dependent phosphoproteome , 2020, Molecular and Cellular Biochemistry.

[2]  L. Cesaro,et al.  Prevalence and significance of the commonest phosphorylated motifs in the human proteome: a global analysis , 2020, Cellular and Molecular Life Sciences.

[3]  M. Plana,et al.  Effects of CK2β subunit down-regulation on Akt signalling in HK-2 renal cells , 2020, PloS one.

[4]  L. Pinna,et al.  Protein Kinase CK2 Subunits Differentially Perturb the Adhesion and Migration of GN11 Cells: A Model of Immature Migrating Neurons , 2019, International journal of molecular sciences.

[5]  S. Szelinger,et al.  Compound heterozygous mutations in SNAP29 is associated with Pelizaeus-Merzbacher-like disorder (PMLD) , 2019, Human Genetics.

[6]  C. Arjona,et al.  Okur‐Chung neurodevelopmental syndrome in a patient from Spain , 2019, American journal of medical genetics. Part A.

[7]  Y. Liu,et al.  Germline de novo variants in CSNK2B in Chinese patients with epilepsy , 2019, Scientific Reports.

[8]  T. Ogata,et al.  Identification of de novo CSNK2A1 and CSNK2B variants in cases of global developmental delay with seizures , 2019, Journal of Human Genetics.

[9]  A. Green,et al.  Extending the phenotype associated with the CSNK2A1‐related Okur–Chung syndrome—A clinical study of 11 individuals , 2018, American journal of medical genetics. Part A.

[10]  R. Pfundt,et al.  Okur‐Chung neurodevelopmental syndrome: Eight additional cases with implications on phenotype and genotype expansion , 2018, Clinical genetics.

[11]  M. Montenarh,et al.  Ecto-protein kinase CK2, the neglected form of CK2. , 2018, Biomedical reports.

[12]  Y. Tsurusaki,et al.  Refining the clinical phenotype of Okur–Chung neurodevelopmental syndrome , 2018, Human Genome Variation.

[13]  L. Cesaro,et al.  Re-evaluation of protein kinase CK2 pleiotropy: new insights provided by a phosphoproteomics analysis of CK2 knockout cells , 2018, Cellular and Molecular Life Sciences.

[14]  M. Flajolet,et al.  CK2 Oppositely Modulates l-DOPA-Induced Dyskinesia via Striatal Projection Neurons Expressing D1 or D2 Receptors , 2017, The Journal of Neuroscience.

[15]  S. Rusin,et al.  Identification of Candidate Casein Kinase 2 Substrates in Mitosis by Quantitative Phosphoproteomics , 2017, Front. Cell Dev. Biol..

[16]  P. Billuart,et al.  CSNK2B splice site mutations in patients cause intellectual disability with or without myoclonic epilepsy , 2017, Human mutation.

[17]  I. Dominguez,et al.  CK2 in Cancer: Cellular and Biochemical Mechanisms and Potential Therapeutic Target , 2017, Pharmaceuticals.

[18]  L. Cesaro,et al.  Exploring the CK2 Paradox: Restless, Dangerous, Dispensable , 2017, Pharmaceuticals.

[19]  H. Rebholz,et al.  CK2—An Emerging Target for Neurological and Psychiatric Disorders , 2017, Pharmaceuticals.

[20]  G. Niehans,et al.  CK2 targeted RNAi therapeutic delivered via malignant cell-directed tenfibgen nanocapsule: dose and molecular mechanisms of response in xenograft prostate tumors , 2016, Oncotarget.

[21]  Matthew Mort,et al.  mutation3D: Cancer Gene Prediction Through Atomic Clustering of Coding Variants in the Structural Proteome , 2016, Human mutation.

[22]  Y. Christen,et al.  The Genetics of Autism Spectrum Disorders -- A Time for Metabolism and Hormones , 2016 .

[23]  L. Pinna,et al.  Proteomics perturbations promoted by the protein kinase CK2 inhibitor quinalizarin. , 2015, Biochimica et biophysica acta.

[24]  A. Gingras,et al.  Systematic investigation of hierarchical phosphorylation by protein kinase CK2. , 2015, Journal of proteomics.

[25]  D. Reinberg,et al.  An AUTS2–Polycomb complex activates gene expression in the CNS , 2014, Nature.

[26]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[27]  Paul Theodor Pyl,et al.  HTSeq—a Python framework to work with high-throughput sequencing data , 2014, bioRxiv.

[28]  C. Sotiriou,et al.  Regulation of DNA methylation patterns by CK2-mediated phosphorylation of Dnmt3a. , 2014, Cell reports.

[29]  J. Hahn,et al.  CK2‐dependent inhibitory phosphorylation is relieved by Ppt1 phosphatase for the ethanol stress‐specific activation of Hsf1 in Saccharomyces cerevisiae , 2014, Molecular microbiology.

[30]  P. Greengard,et al.  Selective Knockout of the Casein Kinase 2 in D1 Medium Spiny Neurons Controls Dopaminergic Function , 2013, Biological Psychiatry.

[31]  E. Nishida,et al.  The Casein Kinase 2-Nrf1 Axis Controls the Clearance of Ubiquitinated Proteins by Regulating Proteasome Gene Expression , 2013, Molecular and Cellular Biology.

[32]  R. Nicoll,et al.  Activated CaMKII couples GluN2B and casein kinase 2 to control synaptic NMDA receptors. , 2013, Cell reports.

[33]  B. Guerra,et al.  Downregulation of protein kinase CK2 induces autophagic cell death through modulation of the mTOR and MAPK signaling pathways in human glioblastoma cells , 2012, International journal of oncology.

[34]  Jesse R. Zaneveld,et al.  RNASTAR: an RNA STructural Alignment Repository that provides insight into the evolution of natural and artificial RNAs. , 2012, RNA.

[35]  C. Götz,et al.  TF--a novel cell-permeable and selective inhibitor of human protein kinase CK2 induces apoptosis in the prostate cancer cell line LNCaP. , 2012, Biochimica et biophysica acta.

[36]  John J. Connolly,et al.  The Genetics of Autism Spectrum Disorders , 2011 .

[37]  O. Livnah,et al.  Nuclear Extracellular Signal-Regulated Kinase 1 and 2 Translocation Is Mediated by Casein Kinase 2 and Accelerated by Autophosphorylation , 2011, Molecular and Cellular Biology.

[38]  Adam Siddiqui-Jain,et al.  CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. , 2010, Cancer research.

[39]  J. Isaac,et al.  Casein Kinase 2 Regulates the NR2 Subunit Composition of Synaptic NMDA Receptors , 2010, Neuron.

[40]  Oded Edelheit,et al.  Simple and efficient site-directed mutagenesis using two single-primer reactions in parallel to generate mutants for protein structure-function studies , 2009, BMC biotechnology.

[41]  Y. Wong,et al.  Identification of chemical inhibitors of protein-kinase CK2 subunit interaction , 2008, Molecular and Cellular Biochemistry.

[42]  D. Seldin,et al.  The Alpha Catalytic Subunit of Protein Kinase CK2 Is Required for Mouse Embryonic Development , 2007, Molecular and Cellular Biology.

[43]  T. Veenstra,et al.  CK2 Is a Component of the KSR1 Scaffold Complex that Contributes to Raf Kinase Activation , 2007, Current Biology.

[44]  L. Pinna,et al.  Protein kinase CK2 phosphorylates and upregulates Akt/PKB , 2005, Cell Death and Differentiation.

[45]  T. Kinsella,et al.  CK2 inhibits apoptosis and changes its cellular localization following ionizing radiation. , 2005, Cancer research.

[46]  D. Litchfield,et al.  The Multiple Personalities of the Regulatory Subunit of Protein Kinase CK2: CK2 Dependent and CK2 Independent Roles Reveal a Secret Identity for CK2β , 2005, International journal of biological sciences.

[47]  D. Guertin,et al.  Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex , 2005, Science.

[48]  Hao Wu,et al.  Protein kinase CK2 is required for dorsal axis formation in Xenopus embryos. , 2004, Developmental biology.

[49]  O. Filhol,et al.  Visualization and molecular analysis of nuclear import of protein kinase CK2 subunits in living cells , 2004, Molecular and Cellular Biochemistry.

[50]  C. Souchier,et al.  Live-Cell Fluorescence Imaging Reveals the Dynamics of Protein Kinase CK2 Individual Subunits , 2003, Molecular and Cellular Biology.

[51]  O. Issinger,et al.  Disruption of the Regulatory β Subunit of Protein Kinase CK2 in Mice Leads to a Cell-Autonomous Defect and Early Embryonic Lethality , 2003, Molecular and Cellular Biology.

[52]  B. Trask,et al.  Identification of a novel gene on chromosome 7q11.2 interrupted by a translocation breakpoint in a pair of autistic twins. , 2002, Genomics.

[53]  O. Issinger,et al.  Crystal structure of human protein kinase CK2: insights into basic properties of the CK2 holoenzyme , 2001, The EMBO journal.

[54]  D. Seldin,et al.  Globozoospermia in mice lacking the casein kinase II alpha' catalytic subunit. , 1999, Nature genetics.

[55]  O. Issinger,et al.  Subcellular localization of protein kinase CK-2 alpha- and beta-subunits in synchronized cells from primary human fibroblasts and established cell lines. , 1993, Cellular & molecular biology research.